When shares of Optimer (NASDAQ: OPTR) jumped up in February on the news that it was seeking "strategic alternatives" -- in other words, looking for a buyer -- Motley Fool health-care analyst David Williamson warned that the company's defining drug, Dificid, has had slow sales, and finding a buyer might not be easy. However, in this video, David tells investors about an article in Bloomberg, reporting that both GlaxoSmithKline (GSK 2.18%) and AstraZeneca (AZN +0.00%) may be interested, which has shares of Optimer up 20%. David explores what Optimer has to offer that may or may not make this buyout worth the buyer's while.
